SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

Glycogen phosphorylase (GP) is a pivotal enzyme responsible for the catabolism of glycogen into glucose, a process intricately linked to blood glucose regulation. In the context of type 2 diabetes, ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases.

Discontinued use and high dosage of alpha-glucosidase inhibitors in combination with metformin was shown to increase risk of psoriasis and psoriatic arthritis in patients with type 2 diabetes compared ...

The final thesis of Professor Lim Soo's team of the Department of Endocrine Metabolism at Bundang Seoul National University ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio SGLT2 inhibition in older patients with ...

Patients with type 2 diabetes newly initiated on a sodium-glucose cotransporter-2 (SGLT2) inhibitor did not have an added risk of fracture at 6 months or 1 year compared with patients started on a ...

ASCO 2021 brings us news of RELATIVITY-047, which tested the combination of anti-PD-1 nivolumab with a drug called relatlimab that is an inhibitor of the lymphocyte activation gene-3 (LAG-3) pathway.

Molecular Tumor Board–Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial The development of the selective RET inhibitors selpercatinib and pralsetinib has ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Receipt of an SGLT-2 inhibitor for type 2 diabetes in ...

The Janus kinase (JAK) inhibitor ruxolitinib (Jakafi) eased the severe inflammatory and dermatologic symptoms of disabling pansclerotic morphea (DPM), an initial clinical series showed. After a series ...